News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
709,135 Results
Type
Article (41986)
Company Profile (331)
Press Release (666818)
Section
Business (210205)
Career Advice (2083)
Deals (36596)
Drug Delivery (100)
Drug Development (82881)
Employer Resources (171)
FDA (16503)
Job Trends (15366)
News (355565)
Policy (33835)
Tag
Academia (2574)
Alliances (51249)
Alzheimer's disease (1306)
Approvals (16461)
Artificial intelligence (173)
Bankruptcy (364)
Best Places to Work (11730)
Biotechnology (213)
Breast cancer (204)
Cancer (1516)
Cardiovascular disease (125)
Career advice (1742)
CAR-T (106)
Cell therapy (311)
Clinical research (66444)
Collaboration (569)
Compensation (306)
COVID-19 (2618)
C-suite (131)
Data (1470)
Diabetes (188)
Diagnostics (6275)
Earnings (86695)
Employer resources (149)
Events (113185)
Executive appointments (473)
FDA (17272)
Funding (511)
Gene therapy (225)
GLP-1 (651)
Government (4457)
Healthcare (18917)
Infectious disease (2714)
Inflammatory bowel disease (116)
Interviews (320)
IPO (16654)
Job creations (4052)
Job search strategy (1488)
Layoffs (445)
Legal (8331)
Lung cancer (222)
Manufacturing (223)
Medical device (13312)
Medtech (13317)
Mergers & acquisitions (20173)
Metabolic disorders (507)
Neuroscience (1670)
NextGen: Class of 2025 (6631)
Non-profit (4519)
Northern California (1859)
Obesity (290)
Opinion (210)
Patents (134)
People (58568)
Phase I (20591)
Phase II (29237)
Phase III (21915)
Pipeline (608)
Postmarket research (2652)
Preclinical (8737)
Radiopharmaceuticals (243)
Rare diseases (292)
Real estate (6243)
Regulatory (22610)
Research institute (2361)
Resumes & cover letters (358)
Southern California (1601)
Startups (3715)
United States (16602)
Vaccines (591)
Weight loss (208)
Date
Today (142)
Last 7 days (840)
Last 30 days (2145)
Last 365 days (35522)
2025 (1418)
2024 (35806)
2023 (40632)
2022 (51797)
2021 (56329)
2020 (54794)
2019 (47400)
2018 (35771)
2017 (33138)
2016 (32664)
2015 (38616)
2014 (32517)
2013 (27630)
2012 (29731)
2011 (30488)
2010 (28500)
Location
Africa (776)
Arizona (209)
Asia (40247)
Australia (6436)
California (4207)
Canada (1538)
China (359)
Colorado (191)
Connecticut (202)
Europe (85684)
Florida (594)
Georgia (142)
Illinois (420)
Indiana (245)
Maryland (683)
Massachusetts (3293)
Michigan (182)
Minnesota (313)
New Jersey (1189)
New York (1195)
North Carolina (796)
Northern California (1859)
Ohio (151)
Pennsylvania (993)
South America (1159)
Southern California (1601)
Texas (613)
Utah (120)
Washington State (432)
709,135 Results for "biostar pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Novotech and Biostar Establish Strategic Partnership Following Biostar’s HKEX Listing
November 13, 2024
·
2 min read
Biotech Bay
100% CBR! FDA Granted ODD to Biostar Pharma’s Utidelone Capsule (UTD2) for the Treatment of Gastric Cancer
Biostar Pharma, Inc., the U.S. subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. which is a synthetic biology driven biopharma company focusing on the development and commercialization of innovative oncology drugs, announced today that their key pipeline product UTD2 (utidelone capsule) had been granted an Orphan Drug Designation (ODD) by the FDA for the treatment of gastric cancer.
March 21, 2024
·
4 min read
Biotech Bay
73% CNS ORR! FDA Granted ODD to Utidelone Injectable (UTD1) from Biostar Pharma for the Treatment of Breast Cancer Brain Metastasis
Biostar Pharma, Inc. announced today that their core pipeline product utidelone injectable (UTD1) had been granted an Orphan Drug Designation (ODD) by the FDA for the treatment of breast cancer brain metastasis (BCBM).
March 29, 2024
·
3 min read
Press Releases
Biostar Announces Completion of Patient Recruitment for US Phase 1 Clinical Study of Utidelone Capsule
September 3, 2024
·
5 min read
BioMidwest
SomaLogic expands into China with groundbreaking Biostar Technology Limited Partnership
SomaLogic, Inc., a leader in proteomics technology, announced that Biostar Technology Limited will be the company’s first authorized site in China to offer the 7,000-plex SomaScan® Assay and provide SomaScan data to their customers.
May 10, 2023
·
4 min read
Biotech Bay
Introducing BIOSTAR® cutting-edge Conventional TBNA (cTBNA) and Endobronchial ultrasound (EBUS) TBNA (EBUS-TBNA) needle: Revolutionizing Minimally Invasive Diagnostic techniques
In a remarkable stride towards advancing medical technology, we are thrilled to announce the launch of our groundbreaking BioStar® Transbronchial Aspiration Needle (TBNA) designed to transform the landscape of minimally invasive diagnostics.
September 8, 2023
·
3 min read
Press Releases
Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.
December 30, 2024
·
11 min read
Press Releases
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of Binding Term Sheet for $27 Million in Funding for HOPE Clinic Acquisitions and Pharmaceutical Operations
January 7, 2025
·
8 min read
Press Releases
Bexion Pharmaceuticals, Inc. Announces Poster Presentation at ASCO GI 2025
January 9, 2025
·
2 min read
Drug Development
Biostar Pharma Announces First Patient Enrolled for Phase 1 Study of Utidelone Capsule (UTD2)--The World’s First Oral Epothilone Anti-Cancer Drug
Biostar Pharma, Inc. is pleased to announce that the first patient has been enrolled today for a Phase 1 clinical study (BG02-2201; NCT05681000) of its proprietary oral formulation product of utidelone, UTD2 (utidelone capsule) in advanced solid tumor patients in the US.
June 12, 2023
·
5 min read
1 of 70,914
Next
